FletcherCV, StaskusK, WietgrefeSW, et al.: Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A, 2014; 111:2307–2312.
2.
EdénA, FuchsD, HagbergL, et al.: HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis, 2010; 202:1819–1825.
3.
PelusoMJ, FerrettiF, PetersonJ, et al.: Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS, 2012; 26:1765–1774.
4.
HammondER, CrumRM, TreismanGJ, et al.: The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV. Am J Epidemiol, 2014; 180:297–307.
5.
CalcagnoA, SimieleM, AlberioneMC, et al.: Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control. Clin Infect Dis, 2015; 60:311–317.
6.
RaffeS, FisherM: The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV. Expert Opin Drug Metab Toxicol, 2015; 11:427–435.
7.
ClinicalTrials.gov Identifier: NCT02251236. Available at https://clinicaltrials.gov/ct2/show/NCT02251236?term=elvitegravir+CSF&rank=1, accessed June12, 2015.
8.
Stribild™ (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) [package insert]. Gilead Sciences, Inc., Foster City, CA, 2012.
9.
CalcagnoA, CusatoJ, SimieleM, et al.: High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: A pharmacogenetic analysis. J Antimicrob Chemother, 2014; 69:241–245.
10.
LetendreSL, MillsAM, TashimaKT, et al.: ING116070: A study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis, 2014; 59:1032–1037.
